FAERS Analysis Probes Tralokinumab Adverse Events in Atopic Dermatitis
A Frontiers pharmacovigilance study applies FAERS disproportionality analysis to tralokinumab adverse events in atopic dermatitis, flagging real-world safety signals beyond Phase III data.